Skip to content
Targazyme logo — company profile

Targazyme

Founded 2008 11 employees Series A Total: $60.00M Biopharma, Biotechnology +2

General Information

Company Name Targazyme
Founded Year 2008
Employees 11
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Targazyme. To contact Targazyme, visit targazyme.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Targazyme compare?

A PDF of Targazyme and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Targazyme soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Targazyme

Targazyme is a San Diego-based, clinical-stage biopharmaceutical company founded in 2008. The company focuses on developing novel enzyme-based platform technologies and products to enhance the clinical efficacy and cost of care outcomes for various medical areas including cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy, and regenerative medicine. Targazyme's clinical-grade fucosyltransferase enzymes and small molecule products (TZ101 and TZ102) are off-the-shelf biologic products used at the point-of-care to treat therapeutic cells immediately before infusion into the patient. The company has received worldwide patents, multiple FDA orphan drug designations, has an open investigational new drug application (IND) with multiple ongoing clinical studies, and a Phase 3 Special Protocol Assessment (SPA) with the FDA. Targazyme has received numerous medical and scientific awards and has partnerships and collaborations with Kyowa Hakko Kirin and Florida Biologix, as well as various medical research institutions including The University of Texas M.D. Anderson Cancer Center, Oklahoma Medical Research Foundation, Texas Transplant Institute, Case Western/University Hospitals, Scripps Hospitals, Fred Hutchinson Cancer Research Center, University of California Los Angeles Medical Center, Stanford University Medical Center, University of Minnesota Medical Center, University of California San Diego Medical Center, Sanford-Burnham Medical Research Institute, Indiana University, Memorial Sloan Kettering Cancer Center, and New York Blood Center. The last investment in Targazyme was a $60.00M Series A investment by Kyowa Kirin and Texas Wide Open for Business on 15 July 2009. Learn more at http://www.targazyme.com.

Business keywords: biopharmaceutical, enzyme-based therapies, cell therapy, immunotherapy, cancer treatment, regenerative medicine, clinical trials, FDA orphan drug designation, partnerships, medical research, biologic products, fucosylation technology, clinical-grade enzymes, IND application, clinical-stage company

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $60.00M 2
Kyowa Kirin, Texas Wide Open for Business
15 Jul 2009

Targazyme Alternatives & Competitors

View All Alternatives
Targazyme vs

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
Targazyme vs

SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer...

Venture round
8 employees
Biotechnology, Life Sciences
Targazyme vs

Seeking New Horizons for Cancer Patients

Grant
8 employees
Biotechnology, Health Care

FAQ About Targazyme

Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene...
Targazyme was founded in 2008.
Targazyme operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical, enzyme-based therapies, cell therapy and immunotherapy.
Targazyme has approximately 11 employees.
Targazyme has completed 1 funding round, raising a total of $60.00M. The latest funding stage is Series A.
Top alternatives and competitors to Targazyme include Prescient Therapeutics, SciTech Development, Inc., Kintara Therapeutics, Inc. NASDAQ: KTRA, Brainstorm Cell Therapeutics, Arcellx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Targazyme and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Targazyme, https://bouncewatch.com/company/targazyme, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout